Elanco Animal Health (ELAN) is back in focus after second quarter 2026 results showed higher sales and net income versus a year earlier, along with slightly raised full year revenue guidance.

The stronger second quarter earnings and slightly higher full year revenue guidance appear to be feeding into Elanco Animal Health's recent share price trend. The company has recorded a 7 day share price return of 4.0% and a 90 day share price return of 13.38%, against a softer 30 day share price return that fell 8.48%. Over longer periods, the stock shows building momentum, with a 1 year total shareholder return of 34.93% and a 3 year total shareholder return of about 2x, even though the 5 year total shareholder return declined 26.77%.

If these results have you thinking about where else growth stories may emerge, it could be a good time to scan for other potential opportunities using the 21 top founder-led companies

After Elanco Animal Health's strong recent run and updated guidance, the stock now reflects significantly more optimism than it did a year ago. The key question for investors is whether the current price still leaves enough potential upside to justify the risks.

Most Popular Narrative: 20.6% Undervalued

Elanco Animal Health's most followed narrative puts fair value at $29.79 per share, compared with the latest close of $23.64. That gap hinges on a specific view of how growth, margins and valuation could evolve from here.

Operational focus on product launches and divesting non core businesses such as the Aqua division has enabled debt reduction and increased investment capacity, which should improve net margins and financial stability. Elanco's strategic focus on leveraging their diversified portfolio and geographic expansion, particularly in key growth markets, is anticipated to maintain balanced revenue growth across both pet health and farm animal markets.

If you want to see what really underpins that fair value, the narrative spells it out. It leans on a specific revenue glide path, a clear margin rebuild story and a richer future earnings multiple than the sector usually commands. The mix of these assumptions is where the $29.79 figure comes from.

Result: Fair Value of $29.79 (UNDERVALUED)

However, Elanco Animal Health still carries real execution risk if new launches like Befrena or Zenrelia underperform expectations, and if higher operating spend keeps pressure on margins.

Next Steps

If this mix of optimism and risk around Elanco Animal Health leaves you undecided, move quickly to review the numbers and shape your own view. To see what the current optimism is based on, start with the 4 key rewards.

Looking for more investment ideas beyond Elanco Animal Health?

If you want to stay ahead of the crowd, use the Simply Wall Street Screener to surface fresh opportunities before they hit everyone else's radar.

• Capture potential upside in overlooked companies by scanning screener containing 20 high quality undiscovered gems that combine strong fundamentals with low market attention.
• Strengthen the quality of your portfolio by focusing on businesses in the solid balance sheet and fundamentals stocks screener (50 results) that can better handle financial pressure.
• Reduce portfolio shocks by screening for 79 resilient stocks with low risk scores that score well on stability and business quality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.